Envelope surface glycoprotein gp120
|
env
|
HIV-1 gp120-induced release of IL-6 is regulated by p38 MAPK, IkappaB-alpha, and p65 NF-kappaB activation in primary human monocyte-derived dendritic cells |
PubMed
|
|
env
|
HIV-1 gp120 activates NF-kappaB by inducing phosphorylation of IkappaBalpha in human astrocyte cells |
PubMed
|
|
env
|
HIV-1 gp120 induces degradation of IkappaBalpha in human astroglial cells |
PubMed
|
|
env
|
The mRNA expression levels for alpha-tubulin, TRADD, IFN-gamma R2, GAS1, MADD, NF-kappaB, I-kappa B, 14-3-3 protein, APaf1, PARP, IGF-1 receptor, RB1, Rb2/p130, ARC, and caspase 6 are upregulated in human neuronal cells after treatment with HIV-1 gp120 |
PubMed
|
|
env
|
HIV-1 gp120/CD4 interaction-induced NF-kappaB activation stimulates the hyperphosphorylation of IkappaB-alpha by IkappaB kinases (IKKs) |
PubMed
|
|
env
|
Overexpression of NF-kappaB inhibitory subunit, IkappaBalpha, completely abrogates gp120-induced COX-2 activity |
PubMed
|
Envelope surface glycoprotein gp160, precursor
|
env
|
I kappa B alpha inhibits HIV replication and gp160 expression by negatively regulating Rev function, most likely acting through a cellular factor involved in Rev transactivation |
PubMed
|
Envelope transmembrane glycoprotein gp41
|
env
|
Exposure of cells (primary human T cells, TZM-bl-2) to HIV gp41 increases phosphorylated NFKBIA (IkappaBalpha) |
PubMed
|
Nef
|
nef
|
HIV-1 Nef ultimately activates NFKBIA and CD28RE via lipid raft mediated AKT1 signaling |
PubMed
|
|
nef
|
HIV-1 Nef induces phosphorylation of NFKIA (IkappaBalpha) |
PubMed
|
|
nef
|
The interaction of HIV-1 Nef with TRAF2, TRAF5, and TRAF6 proteins activates NF-kappaB, leading to the degradation of IkappaB-alpha and the increased phosphorylation of IKK-alpha and IKK-beta in monocyte-derived macrophages |
PubMed
|
|
nef
|
HIV-1 Nef suppresses immunoglobulin class-switch DNA recombination by inducing IkappaBalpha and SOCS proteins, which block CD154, IL-4 and IL-10 cytokine signaling via NF-kappaB and STAT transcription factors |
PubMed
|
|
nef
|
The degradation of I-kappaB alpha in promonocytic cells treated with exogenous HIV-1 Nef results in the activation of NF-kappaB |
PubMed
|
Rev
|
rev
|
I kappa B alpha inhibits Rev function, most likely through a cellular factor involved in Rev transactivation |
PubMed
|
Tat
|
tat
|
HIV-1 Tat degrades NFKBIA (IkappaBalpha) in HUVEC and EA.hy926 cells |
PubMed
|
|
tat
|
HIV-1 Tat causes proteasomal degradation of TIRAP and NFKBIA in THP-1 cells |
PubMed
|
|
tat
|
HIV-1 Tat induces the phosphorylation and degradation of IkappaB leading to the activation of NF-kappa B, an effect that appears to be regulated by Tat induced expression of NOS-2 and NOS-3 |
PubMed
|
|
tat
|
HIV-1 Tat degrades of NFKBIA (IKappaBalpha)) in CRT-MG human astroglioma cells |
PubMed
|
|
tat
|
Primary human Muller glia cells treated with both HIV-1 clade B and clade C Tat induce phosphorylation of IkappaB-alpha |
PubMed
|
|
tat
|
HIV-1 Tat enhances the NFkappaB activity by inhibiting IkappaB-alpha binding to p65 RelA |
PubMed
|
|
tat
|
HIV-1 Tat upregulates the expression of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA, IkappaB alpha) in human primary T cells |
PubMed
|
|
tat
|
HIV-1 Tat enhances the NFkappaB activity and promotes the transcriptional activation of MIP-1alpha by interacting with IkappaB-alpha and p65 RelA |
PubMed
|
|
tat
|
HIV-1 Tat inhibits the LPS-induced activation of NFkappaB p65 via its induction of IkappaBalpha expression, which results in retention of NFkappaB p65 in the cytosol |
PubMed
|
|
tat
|
Amino acids 72 to 287 of IkappaB-alpha are required for Tat inhibition. Amino acids 263 to 269 within the sixth ankrin of IkappaB-alpha are required for the binding to Tat |
PubMed
|
|
tat
|
I kappa B potently inhibits HIV-1 Tat-mediated transactivation of the HIV-1 LTR promoter |
PubMed
|
Vpr
|
vpr
|
HIV-1 Vpr induces phosphorylation of IkappaB-alpha at serine positions 176 and 180 |
PubMed
|
|
vpr
|
HIV-1 Vpr expression results in increased IkappaB-alpha levels in the presence of TNF-alpha treatment in differentiated U937 cells |
PubMed
|
|
vpr
|
HIV-1 Vpr induced an increase in I kappa B alpha message in PBMCs, supporting the notion that Vpr diminishes NF-kappa B activity by upregulating I kappa B alpha transcription, an effect that is linked to Vpr regulation of apoptosis |
PubMed
|
Vpu
|
vpu
|
Vpu from primary isolates inhibits NFKBIA-dependent gene expression similarly to the inhibition observed when NL4-3 Vpu is utilized |
PubMed
|
|
vpu
|
NL4-3 Vpu inhibits NFKBIA but not IRF3 signaling and requires serines at Vpu amino acid positions 52 and 56 to do so |
PubMed
|
|
vpu
|
HIV-1 Vpu stabilizes IkappaB-alpha upon stimulation with TNF-alpha in 293T cells |
PubMed
|
|
vpu
|
HIV-1 Vpu inhibits beta-TrCP-mediated degradation of phosphorylated IkappaB-alpha |
PubMed
|
capsid
|
gag
|
Exposure of human T cells to HIV CA (p24) increases phosphorylated NFKBIA (IkappaBalpha) |
PubMed
|
matrix
|
gag
|
Exposure of cells (primary human T cells, TZM-bl) to HIV MA (p17) increases phosphorylated NFKBIA (IkappaBalpha) |
PubMed
|